Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Standard platinum-based chemotherapy · 1 trial · 1 indication
Progression-free survival (PFS) was defined as the time from randomization to disease progression or death, from any cause. Progressive disease (PD) was defined according to Response Criteria in Solid Tumors (RECIST) version (V) 1.0. For target lesions (TLs), progressive disease (PD) was defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded since the start of treatment. For non-target lesions (NTLs), PD was defined as unequivocal progression of existing NTLs. Participants were censored at the date of last post-baseline (BL) tumor assessment where non-progression was documented. If no post-BL tumor assessment was available, the participant was censored at date of randomization.
The median time, in weeks, from randomization to PFS event. Participants were censored at the date of last post-BL tumor assessment where non-progression was documented. If no post-BL tumor assessment was available, the participant was censored at date of randomization. PFS was estimated using Kaplan-Meier methodology.
| Arm | Type | Description |
|---|---|---|
| Bevacizumab, Chemotherapy | ACTIVE_COMPARATOR | Participants received bevacizumab, 15 milligrams (mg) per (/) kilogram (kg), intravenously (IV), on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received 4 to 6 cycles of a standard platinum-containing regimen of chemotherapy: either gemcitabine, 1250 mg/ square meter (m\^2), IV, on Days 1 and 8 of Cycles 1 through 4 or 6, and cisplatin 80 mg/m\^2, IV, on Day 1 of Cycles 1 through 4 or 6; or paclitaxel, 200 mg/m\^2, IV, and carboplatin area under the curve (AUC) 6 mg/ milliliter (ml) multiplied by (\*) minute (min) on Day 1 of Cycles 1 through 4 or 6. The chemotherapy regimen and number of cycles was up to the discretion of the investigator. |
| Bevacizumab, Erlotinib | EXPERIMENTAL | Participants received bevacizumab, 15 mg/kg, IV, on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received erlotinib, 150 mg, orally (PO), daily until disease progression, unacceptable toxicity, death, or withdrawal. |
| Name | Type | Description |
|---|---|---|
| Erlotinib | DRUG | 150 mg, PO, daily |
| Bevacizumab | DRUG | 15 mg/kg, IV, Day 1 of Cycles 1 through 7 |
| Standard platinum-based chemotherapy | DRUG | At the discretion of the investigator |
Inclusion Criteria: * adult patients, \>=18 years of age; * advanced (stage IIIb and IV) non-small cell lung cancer; * measurable disease; * ECOG PS 0-1. Exclusion Criteria: * prior chemotherapy or treatment with another systemic anti-cancer agent; * radiotherapy within 4 weeks prior to first dos...
Top 20 of 84 competitors
Standard platinum-based chemotherapy is used for the treatment of Non-Small Cell Lung Cancer (NSCLC). It is a small molecule oncology therapy that was studied in a Phase 2 clinical trial in combination with other agents for patients with advanced disease.
Standard platinum-based chemotherapy is developed by Roche Holding AG, which trades under the ticker RHHBY. The company conducted a Phase 2 clinical trial evaluating this treatment regimen in patients with Non-Small Cell Lung Cancer.
Standard platinum-based chemotherapy is in Phase 2 clinical development. It is an investigational treatment for Non-Small Cell Lung Cancer and has completed one Phase 2 trial, but it is not yet approved by regulatory authorities.
Standard platinum-based chemotherapy was studied in one completed Phase 2 clinical trial, NCT00531960. This trial enrolled 124 patients with advanced Non-Small Cell Lung Cancer and was conducted across multiple countries including Australia, Belgium, France, Italy, and the United Kingdom.
No, Standard platinum-based chemotherapy is not the same as Tarceva (erlotinib) or Avastin (bevacizumab). These are separate drugs that were studied in combination with Standard platinum-based chemotherapy in the clinical trial NCT00531960 for Non-Small Cell Lung Cancer.